PL2542224T3 - Doustna kompozycja farmaceutyczna zawierająca eteksylan dabigatranu - Google Patents

Doustna kompozycja farmaceutyczna zawierająca eteksylan dabigatranu

Info

Publication number
PL2542224T3
PL2542224T3 PL11704996T PL11704996T PL2542224T3 PL 2542224 T3 PL2542224 T3 PL 2542224T3 PL 11704996 T PL11704996 T PL 11704996T PL 11704996 T PL11704996 T PL 11704996T PL 2542224 T3 PL2542224 T3 PL 2542224T3
Authority
PL
Poland
Prior art keywords
pharmaceutical composition
oral pharmaceutical
dabigatran etexilate
containing oral
etexilate
Prior art date
Application number
PL11704996T
Other languages
English (en)
Inventor
Sandra Brueck
Jana Paetz
Martin Koeberle
Jutta Strohmeyer
Original Assignee
Ratiopharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ratiopharm Gmbh filed Critical Ratiopharm Gmbh
Publication of PL2542224T3 publication Critical patent/PL2542224T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL11704996T 2010-03-01 2011-02-28 Doustna kompozycja farmaceutyczna zawierająca eteksylan dabigatranu PL2542224T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10155059 2010-03-01
PCT/EP2011/052919 WO2011107427A1 (en) 2010-03-01 2011-02-28 Dabigatran etexilate-containing oral pharmaceutical composition
EP11704996.5A EP2542224B1 (en) 2010-03-01 2011-02-28 Dabigatran etexilate-containing oral pharmaceutical composition

Publications (1)

Publication Number Publication Date
PL2542224T3 true PL2542224T3 (pl) 2014-12-31

Family

ID=43982233

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11704996T PL2542224T3 (pl) 2010-03-01 2011-02-28 Doustna kompozycja farmaceutyczna zawierająca eteksylan dabigatranu

Country Status (13)

Country Link
US (1) US20130052262A1 (pl)
EP (1) EP2542224B1 (pl)
JP (1) JP5801826B2 (pl)
CA (1) CA2791561A1 (pl)
CY (1) CY1115556T1 (pl)
DK (1) DK2542224T3 (pl)
EA (1) EA201201202A1 (pl)
ES (1) ES2509117T3 (pl)
IL (1) IL221742A (pl)
PL (1) PL2542224T3 (pl)
PT (1) PT2542224E (pl)
SI (1) SI2542224T1 (pl)
WO (1) WO2011107427A1 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030181488A1 (en) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
ITMI20110445A1 (it) * 2011-03-22 2012-09-23 Lo Li Pharma Srl Formulazione farmaceutica comprendente inositolo.
ES2895918T3 (es) * 2012-02-21 2022-02-23 Towa Pharmaceutical Europe S L Composiciones farmacéuticas orales de dabigatrán etexilato
CN103304539A (zh) * 2012-03-07 2013-09-18 天津药物研究院 达比加群酯苹果酸盐及其制备方法和应用
EP2740471B1 (en) 2012-12-07 2015-05-27 Hexal AG Oral pharmaceutical composition comprising dabigatran etexilate
IN2013CH05441A (pl) * 2013-11-26 2015-05-29 Aurobindo Pharma Ltd
WO2015145462A1 (en) 2014-03-26 2015-10-01 Cadila Healthcare Limited Pharmaceutical compositions of dabigatran
CN105919962B (zh) * 2015-12-18 2019-01-18 重庆两江药物研发中心有限公司 一种达比加群酯片剂及其制备方法
TR201617984A2 (tr) * 2016-12-07 2018-06-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dabi̇gatranin farmasöti̇k kompozi̇syonlari
CN106491553A (zh) * 2016-12-09 2017-03-15 吉林省博大伟业制药有限公司 一种甲磺酸达比加群酯的新合成工艺
JP2019014712A (ja) * 2017-07-03 2019-01-31 エルメッド エーザイ株式会社 安定なダビガトラン製剤
CN110339193B (zh) 2018-04-04 2022-04-29 上海汉都医药科技有限公司 含达比加群酯的药物组合物及其制备方法
JP2021014411A (ja) * 2019-07-10 2021-02-12 日医工株式会社 安定なダビガトランエテキシラート製剤

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4016254A (en) * 1972-05-19 1977-04-05 Beecham Group Limited Pharmaceutical formulations
PE121699A1 (es) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
US20030181488A1 (en) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
SI1870100T1 (sl) * 2002-03-07 2012-05-31 Boehringer Ingelheim Int Metansulfonat etil estra heksiloksikarbonilamino imino metil fenilamino metil metil H benzimidazol karbonil piridin il amino propionske kisline
US20040029774A1 (en) * 2002-08-06 2004-02-12 Aly Gamay Composition and methods for the treatment of musculoskeletal disorders and collagen and elastin deficiencies
GB0230034D0 (en) * 2002-12-23 2003-01-29 Biochemie Gmbh Organic compounds
DE10339862A1 (de) * 2003-08-29 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
WO2008009639A2 (en) * 2006-07-17 2008-01-24 Boehringer Ingelheim International Gmbh New indications for direct thrombin inhibitors
BRPI0716436B8 (pt) * 2006-08-25 2021-05-25 Boehringer Ingelheim Int sistema de liberação controlada e método para fabricação do mesmo
EP2074112A1 (en) * 2006-10-10 2009-07-01 Boehringer Ingelheim International GmbH Physiologically acceptable salts of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester
AU2008258596B2 (en) * 2007-06-04 2013-02-14 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
US20110123635A1 (en) * 2008-07-14 2011-05-26 Boehringer Ingelheim International Gmbh Method for manufacturing medicinal compounds containing dabigatran
EA201100358A1 (ru) * 2008-08-19 2011-10-31 Бёрингер Ингельхайм Интернациональ Гмбх Дабигатран для чрескожной хирургической катетеризации сердца
CN102292641A (zh) * 2009-02-02 2011-12-21 贝林格尔.英格海姆国际有限公司 冻干的达比加群

Also Published As

Publication number Publication date
US20130052262A1 (en) 2013-02-28
EP2542224B1 (en) 2014-08-13
PT2542224E (pt) 2014-10-03
JP5801826B2 (ja) 2015-10-28
EP2542224A1 (en) 2013-01-09
WO2011107427A1 (en) 2011-09-09
IL221742A (en) 2015-09-24
SI2542224T1 (sl) 2014-10-30
CY1115556T1 (el) 2017-01-04
ES2509117T3 (es) 2014-10-17
EA201201202A1 (ru) 2013-04-30
DK2542224T3 (da) 2014-10-20
CA2791561A1 (en) 2011-09-09
JP2013521244A (ja) 2013-06-10

Similar Documents

Publication Publication Date Title
ZA201209156B (en) Therapeutic oral composition
IL245326B (en) pharmaceutical preparation
ZA201206666B (en) Oral care composition
PL2619182T3 (pl) Kompozycja farmaceutyczna
IL221742A (en) Oral Pharmaceuticals Containing Debigtran Etxylate
IL225457A0 (en) Pharmaceutical composition
ZA201206301B (en) Oral care composition
HUE066526T2 (hu) Új gyógyászati készítmény
PT2579858E (pt) Composição farmacêutica que contém ivabradina
ZA201301920B (en) Pharmaceutical composition
SG11201403875VA (en) Oral pharmaceutical composition
GB201010453D0 (en) Pharmaceutical composition
ZA201303721B (en) Pharmaceutical compositions comprising alisporivir
GB201001911D0 (en) Pharmaceutical composition
HU1000006D0 (en) Improved pharmaceutical composition
GB201019775D0 (en) Pharmaceutical composition